Skip to content

Observation study on the efficacy of immune checkpoint inhibitors in patients with HIV co-infected advanced non-small cell lung cancer

Observation study on the efficacy of immune checkpoint inhibitors in patients with HIV co-infected advanced non-small cell lung cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106341
Enrollment
Unknown
Registered
2025-07-22
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Non-Small Cell Lung Cancer in Patients with HIV

Interventions

The cohort of advanced NSCLC patients without HIV comorbidity:none
The cohort of advanced NSCLC patients with HIV comorbidity:none

Sponsors

Shanghai Public Health Clinical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.The cohort of advanced NSCLC patients without HIV comorbidity: (1) Age >= 18 years; (2) Advanced NSCLC confirmed by tissue or cytological examination; (3) Not infected with HIV as confirmed by standardized tests; (4) Anti-tumor treatment using immune checkpoint inhibitors combined with chemotherapy. 2. The cohort of advanced NSCLC patients with HIV comorbidity: (1) Age >= 18 years; (2) Advanced NSCLC confirmed by tissue or cytological examination; (3) Confirming HIV infection via standardized diagnostic testing. (4) Anti-tumor treatment using immune checkpoint inhibitors combined with chemotherapy.

Exclusion criteria

Exclusion criteria: 1. For individuals with a history of severe hypersensitivity to monoclonal antibodies. 2. Uncontrolled hepatitis B or C infection, active immunosuppressive therapy, or a history of autoimmune diseases requiring systemic treatment. 3. Idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis.

Design outcomes

Primary

MeasureTime frame
Observation of adverse immune events;CD4+T cells;disease control rate, DCR;objective response rate, ORR;progression free survival;

Secondary

MeasureTime frame
CD8+T cells;IL-6;HIV viral load;overall survival;

Countries

China

Contacts

Public ContactRuifang Chen

Shanghai Public Health Clinical Center

chenruifang1106@126.com+86 18117153959

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026